ライフサイエンスコーパス: Sjogren's syndrome

1 (diabetes, thyroiditis); and rheumatologic (Sjogren's syndrome).

2 e diseases (lupus, rheumatoid arthritis, and Sjogren's syndrome).

3 pression, cognitive disorders, arthritis and Sjogren's syndrome).

4 antibodies in the serum resemble autoimmune Sjogren's syndrome.

5 epletion in systemic lupus erythematosus and Sjogren's syndrome.

6 and aberrant histopathology associated with Sjogren's syndrome.

7 ent from inflammation in the pathogenesis of Sjogren's syndrome.

8 mandibular gland (SMG), a critical target of Sjogren's syndrome.

9 no such studies published or in progress for Sjogren's syndrome.

10 immunologic and nonimmunologic mechanisms in Sjogren's syndrome.

11 systemic sclerosis, rheumatoid arthritis, or Sjogren's syndrome.

12 esembles the disease manifestations of human Sjogren's syndrome.

13 tients with systemic lupus erythematosus and Sjogren's syndrome.

14 he systemic symptoms associated with primary Sjogren's syndrome.

15 imilar to that found in humans with lupus or Sjogren's syndrome.

16 en's syndrome, develop an illness similar to Sjogren's syndrome.

17 function that is highly reminiscent of human Sjogren's syndrome.

18 associated with the autoimmune exocrinopathy Sjogren's syndrome.

19 mation and are models for the human disorder Sjogren's syndrome.

20 rimal gland damage in these murine models of Sjogren's syndrome.

21 lands, similar to that in the human disorder Sjogren's syndrome.

22 e antibodies was less in patients with RA or Sjogren's syndrome.

23 ematosus and 125 white patients with primary Sjogren's syndrome.

24 hocytes in the initiation and propagation of Sjogren's syndrome.

25 ation and are a model for the human disorder Sjogren's syndrome.

26 a reactive infiltrate, often associated with Sjogren's syndrome.

27 n spontaneously develops that is a model for Sjogren's syndrome.

28 oimmune response such as that encountered in Sjogren's syndrome.

29 nction of lacrimal glands in mouse models of Sjogren's syndrome.

30 inflammation, and serve as a model for human Sjogren's syndrome.

31 ding insulin-dependent diabetes mellitus and Sjogren's syndrome.

32 hoid infiltrate that occurs in patients with Sjogren's syndrome.

33 or autoimmune insulin-dependent diabetes and Sjogren's syndrome.

34 nection with the autoimmune exocrinopathy of Sjogren's syndrome.

35 provide insight into the immunopathology of Sjogren's syndrome.

36 not satisfy the criteria for a diagnosis of Sjogren's syndrome.

37 milar to those seen in the pseudolymphoma of Sjogren's syndrome.

38 The other was from a patient with secondary Sjogren's syndrome.

39 europathy and the neuropathy associated with Sjogren's syndrome.

40 ell neoplasms that are often associated with Sjogren's syndrome.

41 /lpr mice are a model for the human disorder Sjogren's syndrome.

42 esions and are a model for the human disease Sjogren's syndrome.

43 and IgG-positive cells, resemble lesions of Sjogren's syndrome.

44 ip biopsy findings that met the criteria for Sjogren's syndrome.

45 ce of complete heart block in a patient with Sjogren's syndrome.

46 60 in systemic lupus erythematosus (SLE) and Sjogren's syndrome.

47 targeted in systemic lupus erythematosus and Sjogren's syndrome.

48 nd diseases such as head and neck cancer and Sjogren's syndrome.

49 s, polymyositis/dermatomyositis, and primary Sjogren's syndrome.

50 tients with systemic lupus erythematosus and Sjogren's syndrome.

51 linked to development of type 1 diabetes and Sjogren's syndrome.

52 ses such as systemic lupus erythematosus and Sjogren's syndrome.

53 ce of an infectious environmental trigger in Sjogren's syndrome.

54 lved in both innate and adaptive immunity in Sjogren's syndrome.

55 esults of a large-scale association study of Sjogren's syndrome.

56 in turn may predispose to the development of Sjogren's syndrome.

57 y for systemic lupus erythematosus (SLE) and Sjogren's syndrome.

58 desiccating stress (DS) model that resembles Sjogren's syndrome.

59 ant CD4(+) infiltration in the LG, mimicking Sjogren's syndrome.

60 iduals with systemic lupus erythematosus and Sjogren's Syndrome.

61 ormal T-cell development and activation, and Sjogren's Syndrome.

62 cent confidence interval, 0.59 to 1.73]; and Sjogren's syndrome, 1.42 [95 percent confidence interval

63 ntly more patients presenting with secondary Sjogren's syndrome (15.7%).

64 ported most frequently by PBC cases included Sjogren's syndrome (17.4%) and Raynaud's syndrome (12.5%

65 ot the clinical profile; 7 had lupus, 14 had Sjogren's syndrome, 7 had both, and 23 were asymptomatic

66 athology and aberrant function mimic that of Sjogren's syndrome, a human autoimmune disease character

67 In patients with primary Sjogren's syndrome, a single treatment course of rituxim

68 sclerosis affects 49,000 adults, and primary Sjogren's syndrome affects from 0.4 million to 3.1 milli

69 Sjogren's syndrome alters the protein profile and brings

70 ntal factors that control the development of Sjogren's syndrome, an autoimmune disease mainly involvi

71 dvancing toward nonbiopsy-based diagnosis of Sjogren's Syndrome, an autoimmune disease.

72 In patients with Sjogren's syndrome and a secretory-defect distal renal t

73 nt discoveries from studies in patients with Sjogren's syndrome and animal models suggest a complex i

74 Both Sjogren's syndrome and common variable immunodeficiency

75 en deficiency may promote the progression of Sjogren's syndrome and its associated lacrimal gland inf

76 kappaB signaling as a therapeutic target for Sjogren's Syndrome and other autoimmune diseases.

77 e hormone, may be useful in the treatment of Sjogren's syndrome and other human autoimmune diseases.

78 ntibody-mediated autoimmune diseases such as Sjogren's syndrome and rheumatoid arthritis.

79 s are becoming clearer in conditions such as Sjogren's syndrome and scleroderma.

80 the lymphomas seen in elderly patients with Sjogren's syndrome and SLE.

81 d is an autoantigen present in patients with Sjogren's syndrome and systemic lupus erythematosus.

82 f the statistical model appear to operate in Sjogren's syndrome and systemic sclerosis whereas only t

83 e diseases, including lupus, scleroderma and Sjogren's syndrome, and had a prominent transcriptomic o

84 develop autoantibodies, sialadenitis, as in Sjogren's syndrome, and immune complex-mediated nephriti

85 caused by medications, chronic diseases like Sjogren's syndrome, and medical treatments, such as radi

86 mplementemic urticarial vasculitis syndrome, Sjogren's syndrome, and mixed cryoglobulinemia.

87 ltiple sclerosis (MS), rheumatoid arthritis, Sjogren's syndrome, and myasthenia gravis.

88 mechanistic insight into the development of Sjogren's Syndrome, and suggest the potential of NF-kapp

89 Currently, no effective treatments exist for Sjogren's syndrome, and there is a limited understanding

90 athomechanisms and involvement of viruses in Sjogren's syndrome, and to highlight the areas for futur

91 cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to provide an overall estimate o

92 Currently, there is no cure for Sjogren's syndrome, and treatment is mainly palliative.

93 the lacrimal gland, and the presence of anti-Sjogren's syndrome antigen A and anti-Sjogren's syndrome

94 activated by the La autoantigen, also called Sjogren's syndrome antigen B (SSB).

95 the human Ago2 minimal RISC system to purify Sjogren's syndrome antigen B (SSB)/autoantigen La as an

96 Human La antigen (Sjogren's syndrome antigen B [SSB]) is an abundant multi

97 f anti-Sjogren's syndrome antigen A and anti-Sjogren's syndrome antigen B antibodies in the serum res

98 La antigen (Sjogren's syndrome antigen B) is a phosphoprotein associ

99 The most common symptoms of Sjogren's syndrome are extreme tiredness, along with dry

100 tients with systemic lupus erythematosus and Sjogren's syndrome are influenced by the HLA class II ge

101 Autoimmune myositis, vasculitis and primary Sjogren's syndrome are rare diseases in which these ther

102 tricted autoantigens (e.g., M3R) targeted in Sjogren's syndrome are specifically cleaved by granzyme

103 eratitis or KCS, a condition that is seen in Sjogren's syndrome, are dependent on NF-kappaB, but are

104 ics of systemic lupus erythematosus (SLE) or Sjogren's syndrome as the era of genome-wide association

105 ate of saliva and tear flow in patients with Sjogren's syndrome, as well as improving subjective symp

106 ong similarity to the 52-kD Ro/SSA lupus and Sjogren's syndrome auto-antigen and the RET finger prote

107 In autoimmune exocrinopathy (Sjogren's syndrome), autoantibodies to the intracellular

108 age and the generation of novel fragments of Sjogren's syndrome autoantigens in this form of apoptosi

109 A human La/Sjogren's syndrome-B (hLa)-specific TCR/hLa neo-self-Ag

110 seen in the salivary glands of patients with Sjogren's syndrome, but it is not known whether the micr

111 to implicate viral infection in the cause of Sjogren's syndrome, but there are no definitive studies

112 us to develop a therapy in the treatment of Sjogren's syndrome by increasing the water permeability

113 (95% CI: 0.8, 7.8) for RA, scleroderma, and Sjogren's syndrome combined and 1.9 (95% CI: 0.6, 6.2) f

114 on was increased in PBMCs from patients with Sjogren's syndrome compared with healthy controls.

115 Dry eye disorders, including Sjogren's syndrome, constitute a common problem in the a

116 The criteria for diagnosis of primary Sjogren's syndrome continue to be controversial, leading

117 017), the findings for rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or

118 ch is a common target of the autoimmunity of Sjogren's syndrome, develop an illness similar to Sjogre

119 or autoimmune disorders, and in the case of Sjogren's syndrome directly in saliva, requiring about a

120 hemolytic anemia, interstitial cystitis, and Sjogren's syndrome had higher prevalence rates among pat

121 mothers with systemic lupus erythematosus or Sjogren's syndrome, had a second child with cardiac NL (

122 ogenesis of systemic lupus erythematosus and Sjogren's syndrome has provided a strong rationale to sp

123 Up to 90% of individuals with Sjogren's syndrome have antibodies targeting the Ro 60 a

124 ing excellent oral hygiene, individuals with Sjogren's syndrome have elevated levels of dental caries

125 Recent studies on each of these steps in Sjogren's syndrome have suggested their role in pathogen

126 es), including systemic lupus erythematosus, Sjogren's syndrome, hemolytic anemia, thrombocytopenia,

127 syndrome in 4, systemic lupus erythematosus/Sjogren's syndrome in 1, and undifferentiated autoimmune

128 MCGN was related to primary Sjogren's syndrome in 22.5% of patients and to lymphopro

129 s had manifestations of autoimmune diseases (Sjogren's syndrome in 4, systemic lupus erythematosus/Sj

130 immunosuppressive medications and secondary Sjogren's syndrome in the development of lymphoma in SLE

131 nitive studies are still lacking for primary Sjogren's syndrome, incidental reports indicating potent

132 ncluding systemic lupus erythematosus (SLE), Sjogren's syndrome, inflammatory bowel disease and multi

133 Sjogren's syndrome is a chronic autoimmune disorder of t

134 Sjogren's syndrome is a common autoimmune disease (affec

135 Sjogren's syndrome is a common autoimmune rheumatic dise

136 Sjogren's syndrome is a poorly understood autoimmune inf

137 Sjogren's syndrome is an autoimmune disease characterize

138 t with chronic rheumatoid arthritis (RA) and Sjogren's syndrome is described.

139 Genetic evaluation of Sjogren's syndrome is limited to small studies that have

140 Natural aging, regardless of Sjogren's syndrome, is also another factor that brings a

141 of SLE is advancing rapidly, whereas that of Sjogren's syndrome lags behind considerably.

142 oes not cause lacrimal gland inflammation, a Sjogren's syndrome-like pathology in lacrimal tissue, or

143 lacrimal tissue, leading to inflammation, a Sjogren's syndrome-like pathology, and aqueous tear defi

144 on also increases incidence of a spontaneous Sjogren's syndrome-like pathology, characterized by lymp

145 hepatitis C virus infection clearly causes a Sjogren's-syndrome-like illness.

146 crimal gland lesions in this murine model of Sjogren's syndrome may contribute to the predominantly T

147 nts with rheumatoid arthritis (RA) (n = 80), Sjogren's syndrome (n = 30), polymyositis and dermatomyo

148 nkylosing spondylitis (AS) (n = 10), primary Sjogren's syndrome (n = 6), juvenile chronic arthritis (

149 Sjogren's Syndrome nuclear autoantigen 1 (SSNA1 or NA14)

150 NHL was associated with Sjogren's syndrome (odds ratio (OR) = 13, 95% confidence

151 other autoimmune diseases, including primary Sjogren's syndrome (OR = 2.45 in Chinese, OR = 2.35 in E

152 crinopathy can be encountered alone (primary Sjogren's syndrome) or in the presence of another autoim

153 difference in the prevalence of thyroiditis, Sjogren's syndrome, or Hodgkin's or NHL.

154 h autoimmune disease (P = 0.005), especially Sjogren's syndrome (P = 0.001) and thyroid disease (P =

155 Kingdom, HERV-K113 was found in 15.6% of 96 Sjogren's syndrome patients (p < 0.01) and 11.9% of 109

156 Among Sjogren's syndrome patients who fulfill the European cri

157 rom Sjogren's syndrome patients, 37 from non-Sjogren's syndrome patients), 2 of which were positive.

158 Ninety-two samples were examined (55 from Sjogren's syndrome patients, 37 from non-Sjogren's syndr

159 ents from parental NOD mice or human primary Sjogren's syndrome patients, but not serum IgG from heal

160 pofunction and dry mouth symptoms in primary Sjogren's syndrome patients.

161 s taking place within the salivary glands of Sjogren's syndrome patients.

162 s of labial salivary gland biopsies from two Sjogren's syndrome patients.

163 on injury, Salmonella infection, uveitis and Sjogren's syndrome, PEPITEM reduced T cell recruitment i

164 2 diabetes, B-cell lymphoma, lichen planus, Sjogren's syndrome, porphyria cutanea tarda, rheumatoid-

165 ncluding systemic lupus erythematosus (SLE), Sjogren's syndrome, primary biliary cirrhosis, and activ

166 stemic lupus erythematosus (SLE) and primary Sjogren's syndrome (pSS) are typically characterized by

167 Primary Sjogren's syndrome (pSS) confers increased risk for non-

168 This cytokine is implicated in primary Sjogren's syndrome (pSS) immunopathology because of the

169 Primary Sjogren's syndrome (pSS) is a chronic autoimmune disease

170 Primary Sjogren's syndrome (pSS) is a complex autoimmune disease

171 Primary Sjogren's Syndrome (PSS) is a highly prevalent autoimmun

172 Primary Sjogren's syndrome (pSS) is a prototype of chronic autoi

173 Primary Sjogren's Syndrome (pSS) is an autoimmune disease involv

174 repertoire in the parotid glands of primary Sjogren's syndrome (pSS) patients before and after ritux

175 The association of primary Sjogren's syndrome (pSS) with Major Histocompatibility C

176 veral autoimmune diseases, including primary Sjogren's syndrome (pSS), are associated with an increas

177 still no disease-modifying drug for primary Sjogren's syndrome (pSS).

178 n which a total of 497 subjects with primary Sjogren's syndrome received 150 international units of h

179 cleroderma, systemic lupus erythematosus, or Sjogren's syndrome (relative risk = 2.0, 95% confidence

180 c NHL subtypes were strongly associated with Sjogren's syndrome: salivary gland (OR = 290, 95% CI: 33

181 e and safety of minor salivary gland biopsy, Sjogren's syndrome serves as a prototype model to study

182 onjunctivitis sicca (KCS), autoimmunity, and Sjogren's syndrome (SjS) have yet to be defined.

183 Sjogren's syndrome (SjS) is a chronic autoimmune disease

184 The development of Sjogren's syndrome (SjS) is a dynamic and temporal proce

185 Sjogren's syndrome (SjS) is a human autoimmune disease c

186 detection of patient serum autoantibodies in Sjogren's Syndrome (SjS), a chronic autoimmune disease a

187 The role of complement in the etiology of Sjogren's syndrome (SjS), a human autoimmune disease man

188 s that plays a direct role in development of Sjogren's syndrome (SjS), a systemic autoimmune disease

189 vely, many features of primary and secondary Sjogren's syndrome (SjS), an autoimmune disease affectin

190 s reacting against salivary gland tissues in Sjogren's syndrome (SjS), an autoimmune disease targetin

191 M3R is often the target of autoantibodies in Sjogren's syndrome (SjS), chemical agonists for M3R are

192 al glands (LGs) of male NOD mice, a model of Sjogren's syndrome (SjS), exhibit immune cell infiltrati

193 Sjogren's syndrome-specific autoantibodies (SSA/Ro and S

194 vary gland epithelial cells in patients with Sjogren's syndrome (SS) and in NOD and NODscid mice expr

195 salivary glands of control subjects without Sjogren's syndrome (SS) and patients with SS who had low

196 E) and heart block, as well as patients with Sjogren's syndrome (SS) and systemic lupus erythematosus

197 -associated meibomian gland disease (MGD) or Sjogren's syndrome (SS) aqueous tear deficiency (ATD).

198 ubgroups with meibomian gland disease (MGD), Sjogren's syndrome (SS) aqueous tear deficiency, or neur

199 cular surface in autoimmune diseases such as Sjogren's syndrome (SS) causes an aqueous-deficient dry

200 Salivary glands in patients with Sjogren's syndrome (SS) develop ectopic lymphoid structu

201 44-year-old woman with a 12-year history of Sjogren's syndrome (SS) developed a low-grade mucosa-ass

202 Differences in diagnostic criteria for Sjogren's Syndrome (SS) have led to confusion in the res

203 inflammation accelerates the development of Sjogren's syndrome (SS) in genetically susceptible mice.

204 Sjogren's syndrome (SS) is a chronic autoimmune disease

205 Sjogren's syndrome (SS) is a chronic autoimmune disorder

206 Sjogren's syndrome (SS) is a chronic inflammatory autoim

207 Primary Sjogren's syndrome (SS) is a common chronic autoimmune d

208 Sjogren's Syndrome (SS) is a human autoimmune disease ch

209 Primary Sjogren's syndrome (SS) is a systemic autoimmune disease

210 Sjogren's syndrome (SS) is an autoimmune condition affec

211 Sjogren's syndrome (SS) is an autoimmune disease affecti

212 Sjogren's syndrome (SS) is an autoimmune disease that is

213 hronic inflammation of the ocular surface in Sjogren's syndrome (SS) is associated with a vision-thre

214 Sjogren's syndrome (SS) is characterized by xerophthalmi

215 Patients with Sjogren's syndrome (SS) or systemic lupus erythematosus

216 ogenesis can occur in the salivary glands of Sjogren's syndrome (SS) patients and is associated with

217 ecules are upregulated in salivary glands of Sjogren's syndrome (SS) patients.

218 uropean Cooperative Group (EEC) criteria for Sjogren's Syndrome (SS) should lead to less confusion in

219 Primary Sjogren's syndrome (SS), a chronic autoimmune disorder o

220 Salivary gland inflammation is a hallmark of Sjogren's syndrome (SS), a common autoimmune disease cha

221 toconjunctivitis sicca (non-SS KCS), 32 with Sjogren's Syndrome (SS), and 48 control subjects.

222 (RA), type 1 diabetes mellitus (DM), primary Sjogren's syndrome (SS), and systemic lupus erythematosu

223 6 normal subjects, six subjects with primary Sjogren's syndrome (SS), and three subjects with SS/SLE

224 In Sjogren's Syndrome (SS), inherent glandular defects, aut

225 The mothers had SLE, Sjogren's syndrome (SS), or undifferentiated autoimmune

226 have been reported in patients with primary Sjogren's syndrome (SS), the role of IL-7 in this diseas

227 acrimal and salivary glands, readily induced Sjogren's syndrome (SS)-like KCS in the recipients.

228 e to determine if these intervals recreate a Sjogren's syndrome (SS)-like phenotype.

229 ch as systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS).

230 ated in the affected organs of patients with Sjogren's syndrome (SS).

231 ogy and may occur for many reasons including Sjogren's syndrome (SS).

232 lasia occurs in ocular surface diseases like Sjogren's syndrome (SS).

233 her the Th17/IL-23 system is up-regulated in Sjogren's syndrome (SS).

234 duals with clinical manifestations of SLE or Sjogren's syndrome (SS).

235 that may be used in the detection of primary Sjogren's syndrome (SS).

236 hat etanercept is ineffective in controlling Sjogren's syndrome (SS).

237 thought to be pivotal in the pathogenesis of Sjogren's syndrome (SS).

238 onjunctivitis sicca (non-SS KCS) and 21 with Sjogren's syndrome (SS).

239 tigens recognized by sera from patients with Sjogren's syndrome (SS).

240 nic to NOD, as a potential model for primary Sjogren's syndrome (SS).

241 ated in the salivary glands of patients with Sjogren's syndrome (SS).

242 he restoration of salivary gland function in Sjogren's syndrome (SS).

243 requently found in the sera of patients with Sjogren's syndrome, systemic lupus erythematosus, and co

244 of autoantibodies in patients suffering from Sjogren's syndrome, systemic lupus erythematosus, and ne

245 targeted by autoantibodies in patients with Sjogren's syndrome, systemic lupus erythematosus, and ne

246 hildren appear to be more closely related to Sjogren's syndrome than systemic lupus erythematosus.

247 ated with the most common symptom of primary Sjogren's syndrome, the loss of salivary gland function.

248 In Sjogren's syndrome, the role of B-cell depletion has bee

249 nt part in the autoimmune disease process of Sjogren's syndrome; therefore, several therapies aiming

250 ave been observed in APS1 patients including Sjogren's syndrome, vitiligo, alopecia, uveitis, and oth

251 though with this method, an association with Sjogren's syndrome was not identified.

252 Twelve female patients with primary Sjogren's syndrome were administered rituximab.

253 Risks of RA, scleroderma, and Sjogren's syndrome were elevated both before and after 1

254 Patients with primary Sjogren's syndrome were enrolled in an open-label trial,

255 No papers specific to Sjogren's syndrome were identified.

256 in our understanding of the pathogenesis of Sjogren's syndrome with a focus on the relationship betw

257 y increase UWS flow in patients with primary Sjogren's syndrome, without causing significant adverse